Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7530 | SR 12813 |
| Pregnane X receptor (PXR) agonist (EC50 values are 200 and 700 nM for human and rabbit PXR respectively). Activates the farnesoid X receptor (FXR) at μM concentrations. Displays hypocholesterolaemic activity via enchanced degradation of HMG-CoA reductase. | |
| BCC7535 | NS 1738 |
| Selective positive allosteric modulator of α7 nicotinic acetylcholine receptors. Exhibits no substantial activity for α4β2, α3β3 and α1-containing receptors. Displays cognitive-enhancing properties in vivo. | |
| BCC7537 | Edelfosine |
| Synthetic lysophospholipid analog that selectively inhibits phosphatidylinositol phospholipase C (IC50= 9.6 μM in fibroblasts and adenocarcinoma cells). Also acts as an agonist at platelet-activating factor (PAF) receptors. Antitumor lipid; selectively induces apoptosis in tumor cells, sparing normal cells. | |
| BCC7540 | NSC 109555 ditosylate |
| Selective, reversible, ATP-competitive Chk2 inhibitor (IC50 = 0.2 μM) that displays no effect on a range of other kinases including Chk1 (IC50 > 10 μM). Inhibits histone H1 phosphorylation (IC50 = 0.24 μM) and attenuates mitochondrial ATP synthesis. Exhibits antiproliferative activity in a number of leukemias in vivo. | |
| BCC7542 | YM 750 |
| Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC50 = 0.18 μM). Exhibits hypocholesterolaemic and antiatherosclerotic activity in vivo. | |
| BCC7545 | Alphaxalone |
| A neurosteroid anesthetic that directly activates and potentiates GABAA receptor-activated membrane current (IGABA). Efficacy but not potency is determined by the alpha subunit of the receptor (EC50 values are 1.4, 1.8, 2.1, 2.4 and 2.5 μM for α1β1γ3, α1β1γ1, β1γ1, α2β1γ2L and α1β1γ2L isoforms respectively). | |
| BCC7548 | RO-3 |
| Selective homomeric P2X3 and heteromeric P2X2/3 receptor antagonist (pIC50 values are 7.0 and 5.9 respectively) that exhibits no activity at P2X1, P2X2, P2X4, P2X5 and P2X7 receptors (IC50 > 10 μM). Attenuates nociceptive sensitivity in animal models of pain. Orally active and brain penetrant. | |
| BCC7549 | Mesopram |
| Orally active phosphodiesterase (PDE) 4 inhibitor. Inhibits Th1 cell proliferation and decreases production of IFN-γ, TNF-α, IL-10 and iNOS in vitro. Triggers ovulation and exhibits efficacy against experimental autoimmune encephalomyelitis and murine colitis in vivo. | |
